Participant demographics and baseline characteristics.
pyrexia
A total of 154 healthy participants were randomized to treatment (FMGX: 116, placebo: 38) across both phase 1 studies. This excludes 12 participants from the open-label cohort (cohort 4) since it focused on a different aspect (assessment of DDI potential of FMGX) and will be reported separately. A total of 151/154 participants completed treatments; 2 withdrew consent and 1 withdrew due to moderate pyrexia (considered unrelated to the study drug). Gender distribution varied across cohort groupings and ranged from 30% to 100% male. Participants in each cohort grouping were mostly white (75% to 100%), young adults (23 to 31 years) of normal weight as determined by body mass index (BMI: 22.1 to 24.3 kg/mParticipant demographics and baseline characteristics (safety population)BMI, body mass index; i.v., intravenous; 